Niimi Jun, Takahashi Yurika, Ueda Kotaro, Tasaka Kenta, Tsuruoka Atsushi, Nemoto Fumio, Moriwaki Takuya, Hatayama Kazumi, Otake Mitsuhiro, Naito Hiromichi
Department of Neurosurgery, Funabashi Municipal Medical Center, Funabashi, Chiba, Japan.
Department of Pharmacy, Funabashi Municipal Medical Center, Funabashi, Chiba, Japan.
J Neuroendovasc Ther. 2020;14(3):90-95. doi: 10.5797/jnet.oa.2019-0097. Epub 2020 Feb 12.
In neuroendovascular therapy, clopidogrel resistance and thrombosis are common problems. In such cases, we use prasugrel as rescue medication, and we clarified its usefulness.
We retrospectively investigated 199 consecutive cases of neuroendovascular therapy performed at our hospital from April 2016 to March 2018, and examined the safety and effectiveness of prasugrel.
There were 14 cases of prasugrel administration: six cases of coil embolization for cerebral aneurysm, five cases of carotid artery stenting (CAS), and three other cases.The reasons for prasugrel administration were as follows: emergency stent use in four cases, intraoperative thrombosis in three cases, intra-stent thrombosis after CAS in three cases, and others in four cases. In all cases, it was used in combination with aspirin and the median duration of administration was 212 days. Regarding its safety, there was one hemorrhagic complication at the puncture site for which the involvement of prasugrel was unable to be excluded, but it was improved by conservative treatment and there was no major hemorrhage such as intracranial hemorrhage. Regarding its efficacy, in one case, the thrombus during coil embolization did not completely disappear after prasugrel administration and additional mechanical thrombolysis was required. However, no new thrombosis was observed during prasugrel administration in all 14 cases.
Prasugrel may be useful as a rescue medication in neuroendovascular therapy.
在神经血管内治疗中,氯吡格雷抵抗和血栓形成是常见问题。在此类情况下,我们使用普拉格雷作为挽救药物,并阐明了其有效性。
我们回顾性调查了2016年4月至2018年3月在我院连续进行的199例神经血管内治疗病例,并检查了普拉格雷的安全性和有效性。
有14例使用了普拉格雷:6例脑动脉瘤弹簧圈栓塞,5例颈动脉支架置入术(CAS),以及其他3例。使用普拉格雷的原因如下:4例紧急使用支架,3例术中血栓形成,3例CAS术后支架内血栓形成,以及其他4例。在所有病例中,它都与阿司匹林联合使用,中位给药持续时间为212天。关于其安全性,有1例穿刺部位出血并发症,不能排除普拉格雷的参与,但经保守治疗后好转,且未发生如颅内出血等大出血。关于其疗效,在1例病例中,普拉格雷给药后弹簧圈栓塞期间的血栓未完全消失,需要额外进行机械溶栓。然而,在所有14例病例中,普拉格雷给药期间均未观察到新的血栓形成。
普拉格雷在神经血管内治疗中可能作为一种挽救药物有用。